Health

Wave Life Sciences reports promising results in Duchenne trial

Article Image

Wave Life Sciences (NASDAQ:WVE) has announced positive interim data from its Phase 2 FORWARD-53 clinical trial investigating WVE-N531 for Duchenne muscular dystrophy amenable to exon 53 skipping.

The interim analysis conducted after 24 weeks of 10 mg/kg dosing every two weeks demonstrated substantial dystrophin expression and indicated that the treatment was safe and well-tolerated.

"The high and consistent dystrophin levels at this interim timepoint are compelling and speak to the potential of WVE-N531 for boys amenable to exon 53 skipping, where better therapeutic options are urgently needed," said Anne-Marie Li-Kwai-Cheung, Chief Development Officer at Wave Life Sciences.

Wave plans to complete the trial and obtain feedback from regulators on potential accelerated approval in the first quarter of 2025.

 

Disclaimer
Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.
Publisher
Grafa